New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
0
15

Guess or Gestalt in Major Trauma at St.Emlyn's - St.Emlyn's

I was recently fortunate enough to speak at the the Emergency Medicine Educators Conference in Coventry on a subject that continues to interest me, that of gestalt, judgement and clinical decision making. As I get older I increasingly realise that simply acquiring more knowledge and skills is not enough. What’s really important is how we use that information, how we make decisions, how we make mistakes and how we get it right. I’m also deep in my preparations for a talk at #SMACCUS on ‘Guess, Gestalt or Genius’ and so I’m always on the look out for studies in this area (as there are surprising few). In my talk in Coventry I used the question of when to activate the Major Haemorrhage Protocol (1:1:1 resuscitation as per PROPPR) in trauma patients. Clearly not all patients need it and there are potential harms if we use it on the wrong patients.  
feedproxy.google.com
almost 5 years ago
Preview
2
40

Risk of GI bleeding associated with oral anticoagulants

Determining the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of GI bleeding.  
bmj.com
almost 5 years ago
Preview
0
17

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
almost 5 years ago
Preview
0
13

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Preview
0
15

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
24

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
6

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
14

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
almost 5 years ago
Preview
0
0

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
almost 5 years ago
Preview
0
4

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.  
feeds.bmj.com
almost 5 years ago
Preview
0
1

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.  
feeds.bmj.com
almost 5 years ago
Www.bmj
0
6

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
almost 5 years ago
1
2
51

Intracranial Hemorrhage Vs Subarachnoid Hemorrhage

A useful illustration of causes of Intracranial Hemorrhage versus causes of Subarachnoid Hemorrhage.  
Sarosh Kamal
over 4 years ago
Preview
5
131

Medical School Pathology, Chapter 13

Chapter 13: Red Blood Cells and Bleeding Disorders (Robbins Pathology) Other chapters- http://www.youtube.com/playlist?list=PL5146550A90FFBCEB Video lecture ...  
youtube.com
over 4 years ago
Www.bmj
0
6

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.  
feeds.bmj.com
over 4 years ago
Preview
0
1

Safety of new oral anticoagulants

Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.  
feeds.bmj.com
over 4 years ago
Preview
0
14

How to stop a post-dialysis site bleeding | EMBlog Mayo Clinic

Author: Cameron Wangsgard, MD and Daniel Cabrera, MD   Post-hemodialysis site hemorrhage (PHSH) is often encountered in the emerge…  
emblog.mayo.edu
over 4 years ago
Preview
0
14

Do vaginal packing, tranexamic acid, interventional radiology or other interventions control vaginal bleeding in women with advanced cervical cancer? | Cochrane

Background: Cervical cancer (cancer of the neck of the womb) is the second most common cancer among women throughout the world, accounting for about 500,000 new detected cases and 273,000 deaths every year. Women more commonly present with advanced disease in the developing world, where access to cervical screening programmes is limited. Advanced cancer of the cervix may not be curable and women often need treatment to control distressing symptoms (palliation), such as vaginal bleeding. Bleeding can be severe enough to be life threatening in women with advanced cervical cancer. Management of vaginal bleeding often poses a challenge, especially in the developing world, where access to radiotherapy is limited. Options for palliative treatment of severe vaginal bleeding include interventional radiology treatment (using x-rays to guide the insertion of 'plugs' into blood vessels supplying the cancer) or vaginal packing (where gauze is compacted into the vagina to absorb the blood and apply pressure directly to the cervix), although these are often only partly effective and may cause harm. Vaginal packs can be soaked with formalin, which is a preservative chemical. Other options for treating severe vaginal bleeding include tranexamic acid (a medicine that reduces bleeding that can be given by mouth or by injection) and radiotherapy (high-energy x-ray treatment).  
cochrane.org
over 4 years ago
Preview
0
1

Use of progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding | Cochrane

Review question: This Cochrane review has evaluated whether the levonorgestrel–releasing intrauterine system (LNG IUS) reduces heavy menstrual bleeding and whether it is safe and acceptable.  
cochrane.org
over 4 years ago
Preview
4
176

Introduction to Blood Coagulation

The blood coagulation page provides details of the normal processes of hemostasis and mechanisms for therapeutic intervention in abnormal bleeding  
themedicalbiochemistrypage.org
over 4 years ago